Single Domain Biotherapeutics
Humanised single domains for direct therapeutics and targeted delivery.
LlamdA® & VHHantage Antibodies
LlamdA® and VHHantage VHH are humanised monovalent antibodies.
Small in size (15 kD), biophysically robust and with tunable half-lives these antibodies are ideal for targeting inaccessible epitopes, achieving enhanced tissue penetration, multi-target binding and formatting for payload delivery.
LlamdA® is Isogenica’s proprietary fully synthetic single domain VHH library, built with our precision COLIBRA® technology to eliminate liabilities and provide biophysically robust therapeutic antibodies. The VHHantage library also offers greater diversity, less liabilities and more developable humanised VHH antibodies.
In the early 1990’s researchers discovered that camels and llamas produce heavy-chain only antibodies.
Their small size, high stability and full antigen binding capacity identified them as potentially excellent building blocks for novel non- IgG biotherapeutics.
In 2019 the first VHH biotherapy received FDA approval. Originally discovered and developed by Ablynx, Caplacizumab gained regulatory approval in February 2019. New approvals are expected imminently with a significant and growing pipeline of VHH therapeutics in clinical development.